Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel O. Koralek
Daniel O. Koralek
Agios Pharmaceuticals
Azacitidine
Myeloid leukemia
Internal medicine
Medicine
Pathology
3
Papers
58
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
2018
Journal of Clinical Oncology
Eytan M. Stein
Courtney D. DiNardo
Jun-Ho Jang
Yasushi Miyazaki
Roberto Ovilla-Martínez
Julia Auer
Vickie Zhang
Daniel O. Koralek
Bin Wu
Show All
Source
Cite
Save
Citations (9)
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
2018
Journal of Clinical Oncology
Courtney D. DiNardo
Anthony S. Stein
Eytan M. Stein
Amir T. Fathi
Andre C. Schuh
Pau Montesinos Fernández
Olatoyosi Odenike
Hagop M. Kantarjian
Richard Stone
Robert H. Collins
Giovanni Martinelli
Montserrat Arnan
Bin Wu
Daniel O. Koralek
Jason Van Oostendorp
Jing Gong
Kyle J. MacBeth
Paresh Vyas
Show All
Source
Cite
Save
Citations (22)
Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
2017
Blood
Courtney D. DiNardo
Anthony S. Stein
Amir T. Fathi
Pau Montesinos
Olatoyosi Odenike
Hagop M. Kantarjian
Richard Stone
Daniel O. Koralek
Jason Van Oostendorp
Jing Gong
Ira Gupta
Paresh Vyas
Show All
Source
Cite
Save
Citations (27)
1